专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20090042830A1 NOVEL ONCOGENE, RECOMBINANT PROTEIN DERIVED THEREFROM, AND USES THEREOF 有权
标题翻译：新型重组蛋白，其衍生的蛋白质及其用途
公开(公告)号：US20090042830A1
公开(公告)日：2009-02-12
申请号：US12207298
申请日：2008-09-09
申请人： Akira SAITO , Masahiko Kuroda
发明人： Akira SAITO , Masahiko Kuroda
IPC分类号： A61K31/713 , C07K14/435 , C07K16/00 , A61P35/00 , G01N33/574 , C07H21/02
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No. 1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No. 2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的全部核苷酸序列，其直接涉及由HPV感染宫颈上皮细胞诱导的宫颈癌及其编码的致癌蛋白的氨基酸序列的癌化机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。第2号。

12. 发明申请

US20150315653A9 METHOD FOR INHIBITING SIGNALING MEDIATED BY ERBB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF 审中-公开
标题翻译：用于抑制ERBB2介导的信号传导的方法，用于其的信号抑制剂及其用途
公开(公告)号：US20150315653A9
公开(公告)日：2015-11-05
申请号：US12563241
申请日：2009-09-21
申请人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
发明人： Noriko GOTOH , Masahiko KURODA , Nobuo TSUCHIDA , Makoto WATANABE
IPC分类号： C12Q1/68 , C07H21/00 , C12N15/63 , C07K16/00 , A61P35/00 , C12Q1/02 , C12N5/071 , C07K14/00
CPC分类号： C12Q1/6886 , A61K31/7088 , A61K38/1709 , A61K39/39558 , A61K48/00 , C07K14/4703 , C07K16/32 , C07K2317/24 , C07K2319/02 , C12N9/1205 , C12Q2600/158 , G01N33/5011 , G01N33/5041 , G01N33/57407 , G01N33/57484 , G01N33/57492 , G01N2333/71 , A61K2300/00
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by ErbB2 in a human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into a cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into a cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since ErbB2 is involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供一种抑制人细胞中ErbB2介导的信号传导途径的活化和用于其的信号传导抑制剂的方法。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。上述多肽可以直接引入细胞，或者可以将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于ErbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

13. 发明申请

US20140170648A1 CANCER MARKER, METHOD FOR EVALUATION OF CANCER BY USING THE CANCER MARKER, AND EVALUATION REAGENT 有权
标题翻译：癌症标记，使用癌症标记评估癌症的方法和评估试剂
公开(公告)号：US20140170648A1
公开(公告)日：2014-06-19
申请号：US14039835
申请日：2013-09-27
申请人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI , Seiko IIZUKA , Yoshinori KOSUGI , Kazuma OHYASHIKI , Akihiko TSUCHIDA
发明人： Masahiko KURODA , Masami TANAKA , Kosuke OIKAWA , Takayuki MIZUTANI , Masakatsu TAKANASHI , Seiko IIZUKA , Yoshinori KOSUGI , Kazuma OHYASHIKI , Akihiko TSUCHIDA
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要翻译：本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

14. 发明授权

US08632967B2 Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent 有权
标题翻译：癌症标记，通过使用癌症标记物评估癌症的方法和评估试剂
公开(公告)号：US08632967B2
公开(公告)日：2014-01-21
申请号：US13472190
申请日：2012-05-15
申请人： Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
发明人： Masahiko Kuroda , Masami Tanaka , Kosuke Oikawa , Takayuki Mizutani , Masakatsu Takanashi , Seiko Iizuka , Yoshinori Kosugi , Kazuma Ohyashiki , Akihiko Tsuchida
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.
摘要翻译：本发明提供了用于评估受试者的癌症的发病，临床前期，临床阶段或预后的新型癌症标志物及其评价方法。使用含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA的癌症标记物作为不包括乳腺癌的癌症的标志物。用于评估除乳腺癌之外的癌症的可能性的方法包括检测从受试者收集的生物样品中癌症标志物的表达水平的步骤。在该方法中，癌标记物含有至少一种选自hsa-miR-92和hsa-miR-494的miRNA。

15. 发明申请

US20100062978A1 METHOD FOR INHIBITING SIGNAL TRANSDUCTION, SIGNAL TRANSDUCTION INHIBITOR TO BE USED THEREIN AND USE THEREOF 有权
标题翻译：用于抑制信号传输的方法，其使用的信号传输抑制剂及其用途
公开(公告)号：US20100062978A1
公开(公告)日：2010-03-11
申请号：US12294347
申请日：2007-03-23
申请人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
发明人： Noriko Gotoh , Masahiko Kuroda , Nobuo Tsuchida
IPC分类号： A61K38/16 , C12N5/08 , C07H21/00 , C07K14/00 , C07K7/08 , A61K31/7088 , C12Q1/68 , A61P35/00
CPC分类号： G01N33/57484 , A61K38/00 , A61K48/00 , C07K14/47 , C12N9/1205 , C12Q1/6886 , C12Q2600/106 , G01N2800/52 , Y10S435/96 , Y10S435/968
摘要： An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2β. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.
摘要翻译：本发明的目的是提供抑制人细胞中erbB1或erbB2介导的信号传导途径的活化的方法和用于其的信号传导抑制剂。可以通过包含人FRS2和bgr的PTB结构域或ERK2结合结构域中的至少一个的多肽抑制上述信号传导途径的激活。可以将上述多肽直接引入细胞，或将编码上述多肽的核酸引入细胞以允许多肽在细胞中表达。这样的多肽和核酸可以用作例如信号传导抑制剂。此外，由于erbB1和erbB2涉及癌症的发展，所以上述信号抑制剂也可用作例如抗癌药物。

16. 发明授权

US07358350B2 Oncogene, recombinant protein derived therefrom, and uses thereof 有权
标题翻译：癌基因，从其衍生的重组蛋白及其用途
公开(公告)号：US07358350B2
公开(公告)日：2008-04-15
申请号：US10758562
申请日：2004-01-16
申请人： Akira Saito , Masahiko Kuroda
发明人： Akira Saito , Masahiko Kuroda
IPC分类号： C07H21/02 , C07H21/04
CPC分类号： C07K14/82 , C07K16/32 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158
摘要： The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.
摘要翻译：本发明鉴定了来自人的新型致癌基因的总核苷酸序列，其直接参与由宫颈上皮细胞的HPV感染诱导的宫颈癌和由此编码的致癌蛋白的氨基酸序列的癌变机制，提供编码衍生自新癌基因的致癌蛋白的肽链的全长多核苷酸，其可用于重组生成致癌蛋白质，以及重组产生的致癌蛋白质的肽链。具体地，本发明提供了涉及宫颈癌发展的来自人的新型致癌基因多核苷酸，其包含编码SEQ ID NO：1的氨基酸序列的核苷酸序列。 ID。 1，特别是SEQ ID NO：1的核苷酸序列的多核苷酸。 ID。 2号

17. 发明授权

US09050666B2 End mill 有权
标题翻译：立铣刀
公开(公告)号：US09050666B2
公开(公告)日：2015-06-09
申请号：US13699831
申请日：2011-05-27
申请人： Masahiko Kuroda
发明人： Masahiko Kuroda
IPC分类号： B23C5/10 , B23C5/00
CPC分类号： B23C5/10 , B23C5/1009 , B23C2210/086 , B23C2210/486 , B23C2210/64 , Y10T407/1948
摘要： The invention provides an end mill having an improved chip discharging performance and capable of carrying out excellent cutting machining. The end mill includes an end cutting edge (2) provided on a front end of a tool body (1) which rotates around a central axis, a peripheral cutting edge (4) provided on an outer periphery of the tool body (1), a rake surface of the end cutting edge (2) and the peripheral cutting edge (4), and at least one recess (6), which locally breaks the continuity of the end cutting edge (2) is provided, wherein a wall section (8) which extends toward the rear of the outer peripheral side is provided at least in that area of the rake surface (3) which is closer to the outer peripheral side than the recess (6).
摘要翻译：本发明提供了具有改进的排屑性能并能够进行优异的切削加工的端铣刀。端铣刀包括设置在围绕中心轴线旋转的工具主体（1）的前端的端部切削刃（2），设置在工具主体（1）的外周上的周边切削刃（4）提供端部切削刃（2）和外围切削刃（4）的前刀面以及局部地破坏端部切削刃（2）的连续性的至少一个凹部（6），其中壁部至少在前槽表面（3）的比凹部（6）更靠外周侧的区域中设置有朝向外周侧的后方延伸的区域（8）。

18. 发明授权

US08828964B2 Cancer cell identification marker and cancer cell proliferation inhibitor 有权
标题翻译：癌细胞鉴定标志物和癌细胞增殖抑制剂
公开(公告)号：US08828964B2
公开(公告)日：2014-09-09
申请号：US13613626
申请日：2012-09-13
申请人： Masahiko Kuroda , Masakatsu Takanashi , Kosuke Oikawa
发明人： Masahiko Kuroda , Masakatsu Takanashi , Kosuke Oikawa
IPC分类号： C12N15/113 , C07H21/04
CPC分类号： C12N15/113 , A61K31/7088 , C12N2310/11 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/5011 , G01N33/57496
摘要： Disclosed is an identification marker which can be utilized for detection of various human cancer cells and whose expression closely relates to malignant alteration of cells, and compositions for human cancer treatment which are based on suppression of cancer cell proliferation through inhibition of expression of the identification marker. The marker is human heterochromatin protein 1γ (HP1γ), and the compositions for cancer treatment comprises one or more agents which suppresses the expression of human HP1γ gene, such as siRNAs to human HP1γ.
摘要翻译：公开了可用于检测各种人类癌细胞并且其表达与细胞的恶性改变密切相关的鉴定标记物，以及基于通过抑制识别标志物表达抑制癌细胞增殖的人类癌症治疗用组合物。标记物是人异染色质蛋白1γ（HP1γ），癌症治疗用组合物包含抑制人HP1γ基因（例如人HP1γ的siRNA）表达的一种或多种。

19. 发明申请

US20110262402A1 THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS 审中-公开
标题翻译：治疗和预防治疗药物
公开(公告)号：US20110262402A1
公开(公告)日：2011-10-27
申请号：US12676638
申请日：2008-09-04
申请人： Masahiko Kuroda , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi , Hiroyuki Shirono , Toru Hirado , Kenichi Maeda
发明人： Masahiko Kuroda , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi , Hiroyuki Shirono , Toru Hirado , Kenichi Maeda
IPC分类号： A61K35/12 , A61K35/28 , A61P19/02 , C12N5/00 , C12N5/071
CPC分类号： A61K35/28
摘要： Provided is a pharmaceutical composition and a method for the treatment and/or prophylaxis of arthritis, inter alia, rheumatoid arthritis. The pharmaceutical composition comprises human mesenchymal stem cells, and the method comprises administering an effective amount human mesenchymal stem cells to a patient.
摘要翻译：提供了用于治疗和/或预防关节炎，特别是类风湿性关节炎的药物组合物和方法。药物组合物包含人间充质干细胞，该方法包括向患者施用有效量的人间充质干细胞。

20. 发明申请

US20110070207A1 THERAPEUTIC COMPOSITION FOR ATOPIC DERMATITIS 审中-公开
标题翻译：治疗组合物
公开(公告)号：US20110070207A1
公开(公告)日：2011-03-24
申请号：US12951612
申请日：2010-11-22
申请人： Masahiko KURODA , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi
发明人： Masahiko KURODA , Masakatsu Takanashi , Katsuko Sudo , Shigeki Yamauchi
IPC分类号： A61K35/28 , A61K35/12 , A61P17/00
CPC分类号： C12N5/0663 , A61K2035/124
摘要： A novel type of therapeutic agent, human mesenchymal stem cells, and a composition containing the same for the treatment of atopic dermatitis is disclosed. A method for the treatment of atopic dermatitis in patient is also disclosed.
摘要翻译：公开了一种新型治疗剂，人类间充质干细胞，以及含有它们用于治疗特应性皮炎的组合物。还公开了一种治疗患者特应性皮炎的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式